IGF1R and Ewing sarcoma: Though NT-157 has yet to be approved for use clinically, several IGF-1R inhibitors, including cixutumumab, have proved to be well-tolerated and effective in stabilizing several advanced cancers including Ewing’s sarcoma and adrenocortical carcinoma40–42.